Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: Thomson Reuters StreetEvents

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Otsuka Holdings Co Ltd's Subsidiary Obtains Marketing Approval in Japan for Onglyza Tablets to Treat Type 2 Diabetes; Transfers Rights to Kyowa Hakko Kirin Co., Ltd

Monday, 25 Mar 2013 02:30am EDT 

Otsuka Holdings Co Ltd announced that its subsidiary, Otsuka Pharmaceutical Co., Ltd., has obtained marketing approval for Onglyza Tablets 2.5mg and 5mg(generic name: saxagliptin hydrate) to treat type 2 diabetes. Otsuka signed an agreement with Kyowa Hakko Kirin Co., Ltd in June 2012, transferring to Kyowa Hakko Kirin the exclusive development and marketing rights for Onglyza in Japan. 

Company Quote

-27.5 -0.75%
4 Mar 2015